Cancer patients are waiting longer for the most innovative treatments to reach the clinic

Written by Louis Gautier, Future Science Group

A team of researchers from the Institute of Cancer Research (ICR) have analyzed access to cancer treatments licensed through the European Medicine Agency (EMA) and found that, although more drugs are being licensed, treatments are taking longer to progress through clinical trials and receive approvals from drug regulation bodies. The study, published in Drug Discovery Today, gives an overview of many aspects related to access to treatment. The research particularly highlights issues with clinical trial and licensing regulations, NICE appraisal and EMA authorization delays, and how the most innovative cancer treatments are suffering the most. Study leader Paul Workman, of...

To view this content, please register now for access

It's completely free